Poor
Mostly Aligned
Patient Risk:
Low
Summary
The response makes multiple claims about generic availability, patents/exclusivity, and a patent-tracking website. None of these topics are supported by the provided FDA prescribing information excerpts, so most claims are unsupported/absent from the label.
Category Scores
Accurate Statements
Eucrisa is a prescription ointment whose active ingredient is crisaborole.
Supported by provided label excerpt section 'DRUG / ACTIVE INGREDIENT(S)' indicating active ingredient crisaborole 2% w/w (not from numbered label sections, but included in prompt content).
Unsupported Statements
Whether a “generic Eucrisa” is available depends on whether other companies have an approved generic (or a pharmacy-available alternative approved by regulators) for crisaborole ointment.
No information in the provided prescribing information excerpts addresses generic availability or regulatory/pharmacy alternative timing.
Patent and exclusivity situation is a key factor in when a true generic can enter the market.
The provided prescribing information excerpts do not discuss patents, exclusivity, or market entry of generics.
Generic availability for prescription dermatology drugs like Eucrisa typically hinges on patent and exclusivity timelines.
The provided prescribing information excerpts do not discuss patent/exclusivity-driven generic availability.
Patent/exclusivity timelines for Eucrisa can include additional barriers such as “secondary” patents.
The provided prescribing information excerpts do not mention patents, exclusivity, or secondary patents.
DrugPatentWatch.com tracks patent coverage and provides date-focused references related to Eucrisa (crisaborole) that can be used to estimate when generic entry could be possible.
The provided prescribing information excerpts do not mention DrugPatentWatch.com or any patent-tracking resource.
Contradictions
Important Omissions
If the intent was to answer questions about EUCRISA prescribing (e.g., indication, dosing, contraindications, warnings, adverse reactions), the response omitted relevant on-label details from the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims primarily concern generic/patent availability and a website, rather than clinical dosing, contraindications, or safety/monitoring instructions. No direct patient-harm instructions or dosing changes were stated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most claims are absent from the provided FDA prescribing information excerpts (generic/patent/exclusivity and DrugPatentWatch.com statements are not supported by the label content provided).
Suggested Improvement
Limit statements to information contained in the provided prescribing information (e.g., active ingredient, indication, dosing, contraindications, warnings/precautions, and adverse reactions). If discussing generic availability/patents, cite sources external to the prescribing information rather than presenting them as label-based facts.